Adamas Pharmaceuticals, Inc. (ADMS) Social Stream



Adamas Pharmaceuticals, Inc. (ADMS): $8.22

0.06 (+0.74%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ADMS to Watchlist
Sign Up

Adamas Pharmaceuticals Inc (ADMS) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Adamas Pharmaceuticals Inc.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
8 $9.1 $3 $7.6 $8.17 -6.98%
8 $9.1 $3 $7.6 $8.17 -6.98%

The Trend in the Analyst Price Target


Over the past 33 weeks, ADMS's average price target has gone down $2.84.

ADMS reports an average of 80.28% for its upside potential over the past 18 months.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-11-17 8 9.1 3 7.60 8.20 -7.32%
2021-04-03 5 20.0 3 10.44 5.15 102.72%
2020-06-04 NA 20.0 3 9.17 NA NA%

ADMS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3.13 0 0 7 0 0 8

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ADMS as an investment opportunity.

  • The upside potential (average analyst target price relative to current price) of ADMS is greater than 1.5% of Pharmaceutical Products stocks.
  • The number of analysts covering the stock of ADMS is greater than 95.26% of stocks in the small market cap category.
  • Adamas Pharmaceuticals Inc's average analyst price target is higher than 9.05% of all US stocks.
  • The variance in analysts' estimates of ADMS is lower than 10.08% of all US stocks.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Adamas Pharmaceuticals Inc are ALKS, TEVA and CLVS.

Is ADMS a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!